Kosan ends KOS-862 NSCLC development

KOSN discontinued development of KOS-862 (Epothilone D) to treat non-small cell lung cancer (NSCLC) after the compound did not meet the primary endpoint of tumor response in a Phase II trial. KOSN sai...